



Dr. Raymond Petryshyn is currently a Program Director in the Coordinating Center for Clinical Trials of the National Cancer Institute (NCI). The responsibility of the Center is to implement and facilitate the restructuring of NCI's clinical trials enterprise. The restructuring plan recommended by the Clinical Trials Working Group Report has about 22 initiatives. Among other initiatives, Dr. Petryshyn was involved in establishing the Gynecologic Cancer Steering Committee, establishing criteria for prioritizing and funding essential correlative studies through the Biomarkers, Imaging and Quality of Life Studies Funding Program (BIQSFP) for phase III trials, coordinating State-of-the-Science meetings in

gynecologic cancer, develop strategies to reduce barriers to timely opening of clinical trials, and developing funding mechanisms for fostering collaborations across NCI's clinical trials network.

Dr. Petryshyn joined the NCI in 2000 as a Scientific Review Administrator in the Division of Extramural Activities. The position, also known as Health Scientist Administrator was in the Resources Review and Training Branch. He was primarily responsible for managing the site visit review of Cancer Centers through out the United States.

Before joining the NCI, Dr. Petryshyn was an Associate Professor of Biochemistry and Molecular Biology in the Department of Biochemistry at George Washington University School of Medicine and Associate Professor of Pediatrics at the Children's Research Institute. Prior to joining George Washington, he was a faculty member at the State University of New York Medical School at Syracuse where he conducted research and taught medical and graduate school.

Dr. Petryshyn's principal area of research interest is in the regulation of cell growth and differentiation by protein phosphorylation. To this end, he has been involved in the development of strategies for *ex-vivo* expansion of hematopoietic and other embryonic stem cells and has published extensively on the role of RNA: protein interaction in signaling cell growth and differentiation, apoptosis, and antiviral responses. His research has contributed to development of potential strategies for the treatment of cancer by combinational drug approaches that involve cytokines and therapeutic peptides. He has published numerous scientific articles in peer-reviewed journals, book chapters, reviews and abstracts. Dr. Petryshyn holds two patents on biological compounds and has been supported by funding from the NCI.

Dr. Petryshyn's academic background includes a B.Sc. degree and Ph.D. degree in biology and biochemistry both from York University in Toronto, Canada. He completed post – doctoral training at MIT as a NATO fellow and was a research associate in the Harvard University – MIT Program in Health Science and Technology.